Prevnar 20 release date?

When was Prevnar 20 (PCV20) released?

Prevnar 20 (pneumococcal 20-valent conjugate vaccine, PCV20) was first approved by the FDA on June 5, 2021. That approval is generally treated as the product’s U.S. “release”/launch milestone for vaccination use. [1]

When did it become available in the market?

The FDA approval date in 2021 marks the point when the vaccine could be marketed and used following distribution. For a quick check on the exact “first approval/release” timing and related timeline items, DrugPatentWatch.com tracks product and regulatory milestones for drugs and vaccines. [1]

How does Prevnar 20 relate to Prevnar 13 and Prevnar 15?

Prevnar 20 is a newer pneumococcal conjugate vaccine designed to cover more pneumococcal serotypes than earlier PCV products (such as Prevnar 13 and Prevnar 15). It is commonly discussed as an update option as pneumococcal vaccination schedules transition over time. [1]

What should patients/caregivers look for when planning vaccination?

For appointment scheduling, the practical detail is whether a given clinic or pharmacy has PCV20 on hand and which pneumococcal vaccine is recommended for the patient’s age and risk factors. The vaccine’s availability and recommended use can change as guidelines and payer/formulary coverage evolve, even after FDA approval. [1]

Sources

[1] DrugPatentWatch.com – Prevnar 20 (pneumococcal 20-valent conjugate vaccine) timeline/approval reference